论文部分内容阅读
目的观察依达拉奉联合奥扎格雷钠治疗急性脑梗死(ACI)的疗效。方法将140例ACI患者随机分为治疗组和对照组。两组患者均给予调整血压、血糖、血脂、减轻脑水肿、防止并发症、阿司匹林等常规治疗。在此基础上,治疗组加用奥扎格雷钠80 mg,静脉滴注,1次/d,依达拉奉30 mg,静脉滴注,2次/d,14 d为一疗程;对照组加用复方丹参20 ml,胞二磷胆碱0.75 g,分别静脉滴注,均1次/d,14 d为一疗程。观察两组治疗后临床神经功能缺损程度评分、日常生活能力(ADL)评分及临床疗效。结果治疗组总有效率91.4%(64/70),对照组总有效率80.0%(56/70),两组对比差异有统计学意义(P<0.05)。治疗组与对照组相比,治疗后临床神经功能缺损程度评分明显下降,ADL评分明显上升,差异均有统计学意义(P<0.01)。治疗组出现2例肝功能损害,停药后自行恢复正常。结论依达拉奉联合奥扎格雷钠治疗ACI能有效改善神经功能、临床症状及生活质量,疗效十分显著、安全性较高,不良反应少而轻,值得推广应用。
Objective To observe the efficacy of edaravone and ozagrel sodium in the treatment of acute cerebral infarction (ACI). Methods 140 cases of ACI patients were randomly divided into treatment group and control group. Two groups of patients were given to adjust blood pressure, blood glucose, blood lipids, reduce brain edema, prevent complications, aspirin and other conventional treatment. On this basis, the treatment group plus sodium ozagrel 80 mg, intravenous infusion, 1 / d, edaravone 30 mg, intravenous infusion, 2 times / d, 14 d for a course of treatment; control group plus With compound Danshen 20 ml, citicoline 0.75 g, respectively, intravenous infusion, were 1 / d, 14 d for a course of treatment. The clinical neurological deficit score, ADL score and clinical effect were observed after treatment. Results The total effective rate was 91.4% (64/70) in the treatment group and 80.0% (56/70) in the control group. The difference between the two groups was statistically significant (P <0.05). Compared with the control group, the score of clinical neurological deficit in treatment group decreased significantly and the ADL score increased significantly, with significant difference (P <0.01). Treatment group 2 cases of liver damage, self-recovery after withdrawal. Conclusion The combination of edaravone and ozagrel sodium can effectively improve the neurological function, clinical symptoms and quality of life of patients with ACI. The curative effect is very significant, the safety is high, and the adverse reactions are few and light, which is worth popularizing and applying.